Iris BioTechnologies launches Health Passport for personalized and
28 January 2009
Iris BioTechnologies (OTCBB:IRSB) has launched its proprietary
BioWindows 2.0 to further the progress of personalized and targeted
BioWindows is a HIPAA compliant, web based, medical information
storage system that allows participants to grant selective or full
sharing capabilities of their confidential medical and lifestyle
information to physicians or family members anywhere in the world.
This allows families to build multi-generational medical family trees
that will help assure that they receive more personalized care now and
in the future — the right medical treatment for the right patient at the
right time. Many users of the system consider it their essential
'Medical Passport' as they and their children and grandchildren
participate in our increasingly global society.
The other essential tool for personalized medicine is the ability to
measure the behaviour of the many genes that are malfunctioning in any
particular disease. The major diseases that inflict so much pain and
suffering on our population are not caused by the inheritance of faulty
genes but by genes malfunctioning over time due to lifestyle and other
easily measured factors. The Iris Nano-Biochip platform is designed to
clinically measure each patient’s unique genomic profile.
Combining these two tools, BioWindows and the Nano-Biochip, will
offer physicians a unique perspective concerning the relationship of a
patient’s genes and their lifestyle dynamics, according to Mr. Chin.
Armed with this information clinicians can truly personalize their
medical treatments raising the quality of our health care system and
lowering its cost.
Last month, Iris BioTechnologies was selected, through a competitive
screening process, by the Biotechnology Industry Organization (BIO) to
present at the Eleventh Annual BIO CEO & Investor Conference in New York
on February 9-10, 2009. “We are looking forward to presenting BioWindows
2.0 and our Nano-Biochip technology platform at this major investor
conference,” said Mr. Chin, CEO of Iris BioTechnologies.
Alan Eisenberg, executive vice president, Emerging Companies &
Business Development at BIO, said, “These leading companies represent
the industry’s most promising investment opportunities with late-stage
clinical pipelines, well established business strategies or strong M&A
potential. Selected companies are also distinguished by significant
opportunities for value creation with near-term clinical, regulatory and
corporate catalysts that will help to support our industry through the
current economic downturn.”
Bookmark this page